ONCY
NASDAQOncolytics Biotech Inc.
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
News · 26 weeks55+300%
2026-04-192026-10-11
Mix2190d
- SEC Filings11(52%)
- Other10(48%)
Latest news
25 items- SECSEC Form 8-K filed by Oncolytics Biotech Inc.8-K - ONCOLYTICS BIOTECH INC (0001129928) (Filer)
- PROncolytics Biotech® Provides Update on GOBLET Study Clinical Data and Final PanCAN Grant PaymentCompletion of enrollment earlier this year and expected final PanCAN grant payment this quarter mark successful completion of a key phase of Cohort 5 Final Cohort 4 results expected in Q4 2026; initial Cohort 5 results expected in the first half of 2027 The Company will use the clinical data to focus and guide its strategy to combine pelareorep with a checkpoint inhibitor in gastrointestinal and additional tumors SAN DIEGO, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, today announced an update regarding the status of its GOBLET Phase 1/2 study, including timing for
- PRCancer Drug Spending Is Headed Past $400 Billion as Colorectal and Pancreatic Cancers Move Up the Research AgendaSAN DIEGO, Oct. 14, 2026 /CNW/ -- Equity Insider News Commentary - Global spending on cancer medicines reached $252 billion in 2024 and is forecast to exceed $400 billion by 2028, according to the IQVIA Institute, with the United States accounting for roughly 46% of the total. The pace of new treatments has picked up with it: about 150 new active substances entered the U.S. oncology market between 2015 and 2024, and launch activity in 2020 to 2024 ran nearly 40% ahead of the prior five years. Active Companies from around the markets with current developments this week include: Oncolytics Biotech, Inc. (NASDAQ:ONCY), Revolution Medicines, Inc. (NASDAQ:RVMD), Eli Lilly and Company (NYSE:LLY),
- SECSEC Form 8-K filed by Oncolytics Biotech Inc.8-K - ONCOLYTICS BIOTECH INC (0001129928) (Filer)
- PROncolytics Biotech® Secures Patent Protection to Late 2040s and Provides Intellectual Property Portfolio UpdateNew method of use patent covering pelareorep as an immunotherapy for cancer has been issued in several countries, with U.S. issuance expected in the near term Three patent applications are pending, including two method of use with one expected to be converted to a Track One application this quarter Company expects to add a new composition of matter patent covering "next generation" pelareorep SAN DIEGO, Oct. 12, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, today provided an update on its intellectual property strategy, outlining progress on new method of use patents and plan
- SECSEC Form DEFA14A filed by Oncolytics Biotech Inc.DEFA14A - ONCOLYTICS BIOTECH INC (0001129928) (Filer)
- SECSEC Form DEF 14A filed by Oncolytics Biotech Inc.DEF 14A - ONCOLYTICS BIOTECH INC (0001129928) (Filer)
- SECOncolytics Biotech Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - ONCOLYTICS BIOTECH INC (0001129928) (Filer)
- PROncolytics Biotech® Announces Publication Demonstrating Pelareorep Creates Immune Responses in Liver Cancer That Make Tumors Susceptible to ImmunotherapySAN DIEGO, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, today announced data published in the Proceedings of the National Academy of Sciences show pelareorep’s ability to change an immunologically inactive liver cancer tumor microenvironment into one that is immunologically active and potentially susceptible to immune-based therapy. The academic paper titled "MicroRNA-driven regulation of immunosuppressive microenvironment in hepatocellular carcinoma" was published in Proceedings of the National Academy of Sciences on September 28, 2026 (link to the paper). Pelareorep
- SECOncolytics Biotech Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - ONCOLYTICS BIOTECH INC (0001129928) (Filer)
- PROncolytics Biotech® Reports Accelerating Enrollment in Randomized REO 033 RAS-Mutant, MSS Colorectal Cancer StudySubstantially all planned REO 033 clinical sites are now activated, with multiple patients currently on study Company expects to have sufficient Part A data to provide an interim clinical update by year-end 2026 FDA alignment provides potential path to accelerated approval based on objective response rate and full approval based on progression-free survival SAN DIEGO, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, today announced continued clinical and operational progress in REO 033, its randomized study evaluating pelareorep in second-line RAS-mutant, microsa
- PRKRAS Inhibitor Market Projected to Reach $7.8 Billion by 2034SAN DIEGO, Sept. 28, 2026 /CNW/ -- Equity Insider News Commentary - For most of the last four decades, RAS was the target oncology could not hit. That has changed quickly, and the commercial numbers are starting to follow. According to DelveInsight, the KRAS inhibitors market across the seven major markets was valued at approximately $526 million in 2025 and is projected to reach approximately $7.85 billion by 2034, a compound annual growth rate of roughly 35% over its 2024 to 2034 forecast period, with the United States expected to account for nearly 70% of the total. As the first generation of RAS-targeted drugs gives way to broader multi-selective inhibitors, the field's central question
- PRThree Nasdaq Cancer Developers Under $10 Advance Clinical ProgramsDENVER, Sept. 11, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) – Recent cancer treatment advances span new FDA approvals and ongoing Phase 2 and Phase 3 clinical programs. NeOnc Technologies Holdings (NASDAQ:NTHI), BriaCell Therapeutics (NASDAQ:BCTX) and Oncolytics Biotech (NASDAQ:ONCY) have reported clinical and regulatory developments across brain, breast and colorectal cancer, and all three have recently traded below $10. NeOnc: Positive Phase 2a brain cancer results The single-arm, open-label study enrolled 24 patients with recurrent or progressive Grade III or IV IDH1-mutant glioma. In its August 12 announcement, NeOnc reported six-month progression-free survival of 48.9% using
- SECOncolytics Biotech Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - ONCOLYTICS BIOTECH INC (0001129928) (Filer)
- PROncolytics Biotech® Announces Positive Preclinical Results Combining Pelareorep with a Pan-RAS Inhibitor in Colorectal CancerPreclinical results demonstrate pelareorep activity is maintained in the presence of RAS inhibition Findings support further evaluation of pelareorep’s potential to deepen and prolong responses to RAS-targeted therapy SAN DIEGO, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, today announced positive preclinical results evaluating pelareorep in combination with a pan-RAS inhibitor in a RAS-driven colorectal cancer model. During the initial treatment period, when pelareorep was administered every other day, pelareorep, the pan-RAS inhibitor and the combination each red
- SECOncolytics Biotech Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - ONCOLYTICS BIOTECH INC (0001129928) (Filer)
- PROncolytics Biotech® Aligns with FDA on Registrational Path for Second-Line RAS-Mutant MSS Colorectal CancerFDA written feedback provides alignment on a potential pivotal Part B expansion of the ongoing REO 033 study Proposed pathway offers potential accelerated approval based on objective response rate and progression-free survival supporting full approval Pivotal expansion to follow initial clinical data from the ongoing randomized Part A SAN DIEGO, Aug. 18, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, today announced that it has received written feedback from the U.S. Food and Drug Administration ("FDA") regarding the design of a potential pivotal Part B expansion of REO 033,
- SECSEC Form 10-Q filed by Oncolytics Biotech Inc.10-Q - ONCOLYTICS BIOTECH INC (0001129928) (Filer)
- SECOncolytics Biotech Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits8-K - ONCOLYTICS BIOTECH INC (0001129928) (Filer)
- SECOncolytics Biotech Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - ONCOLYTICS BIOTECH INC (0001129928) (Filer)
- PROncolytics Biotech® Receives Fast Track Designation for Pelareorep in Second-Line and Later Anal CancerDesignation supports development in an estimated $1 billion market where there are no FDA-approved therapies for patients whose disease progresses following first-line standard of care therapy Third Fast Track designation in gastrointestinal cancers strengthens Oncolytics’ regulatory momentum and continues to advance the Company’s path toward registration SAN DIEGO, July 20, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company, today announced that the U.S. Food and Drug Administration ("FDA") has granted Fast Track designation to pelareorep in combination with a checkpoint inhibitor for the treatment of p
- SECOncolytics Biotech Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - ONCOLYTICS BIOTECH INC (0001129928) (Filer)
- PROncolytics Biotech® Reports FDA Regulatory Milestone and Strong Clinical Progress in Randomized RAS-Mutant MSS Colorectal Cancer TrialHalf of planned clinical sites will be activated this month; more than 20 patients have been pre-identified across participating centers Company to hold Type D meeting with FDA to discuss a potential registrational pathway through the addition of Part B to the existing REO 033 trial design Part B will be a randomized study designed to support potential accelerated and full approval SAN DIEGO, July 13, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) ("Oncolytics" or the "Company"), a clinical-stage company developing pelareorep, an investigational, systemically active immunotherapy that promotes potentially protective immune responses, including the upregulation of key in
- SECOncolytics Biotech Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits8-K - ONCOLYTICS BIOTECH INC (0001129928) (Filer)
- SECOncolytics Biotech Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - ONCOLYTICS BIOTECH INC (0001129928) (Filer)
ONCY FAQ
6 questionsWhat does Oncolytics Biotech Inc. do?
Oncolytics Biotech Inc., a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an immuno-oncology viral-agent for the treatment of solid tumors and hematological malignancies. The company has collaboration agreements with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and avelumab, a human anti-PD-L1 antibody for the treatment of hormone-receptor positive, human epidermal growth factor 2-negative metastatic breast cancer; and PrECOG LLC...Where does ONCY stock trade?
Oncolytics Biotech Inc. (ONCY) is listed on NASDAQ.What sector and industry is ONCY in?
Oncolytics Biotech Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about ONCY?
Oncolytics Biotech Inc. has had 2 recent analyst actions on file. The most recent action was from Lake Street: Buy with a $700.00 price target on 2025-08-13. Recent price targets range from $300.00 to $700.00.What companies are similar to ONCY?
Notable peers in the same industry include LEGN (Legend Biotech Corporation), PBYI (Puma Biotechnology Inc), FBIO (Fortress Biotech Inc.), MBRX (Moleculin Biotech Inc.). Compare ONCY side-by-side with any of them on Quantisnow.How can I track ONCY on Quantisnow?
Quantisnow aggregates Oncolytics Biotech Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ONCY to receive live email and push alerts on every new disclosure.